Danish mHealth solution from Monsenso participates in major R-LiNK Study
The EU-programme Horizon 2020 is one of the largest programmes within research and innovation worldwide. Monsenso's mHealth solution is now part of the R-LiNK study, a major new study for optimising treatment response to lithium.
R-Link is a multimodal approach to studying lithium initiation, and identifying important biomarkers from receiving lithium treatment. The comprehensive study aims to identify factors related to better responses, safety, and tolerability of lithium treatment. As part of the study the Monsenso mHealth solution will be implemented for 300 participants across 15 centres all over Europe.
- "Ensuring adherence to medical treatment on an individual level is key to a successful mental health treatment. Our mHealth solution will contribute to this study by promoting medical adherence, through providing easy, personalised self-monitoring and medication tracking, as well as medication reminders." said Thomas Lethenborg, CEO of Monsenso.
Future health technologies
The Monsenso mHealth solution will be involved in the phase of the study that will conduct a qualitative and quantitative study on the acceptability and efficacy of connected ecological devices to monitor mood, lithium levels, symptoms, daily behavior, and enhance patient adherence. Therefore, the solution will include data collection of lithium adherence and outcome/behavior reporting (via sensor data and daily self-assessment).
- "Mobile health technology can provide new insight into the treatment of mental health and disorders, and mobile phone usage can also provide important new biomarkers for affective disorders." said Professor Lars Kessing, of the Psychiatric Center Copenhagen and the University of Copenhagen, Faculty of Health Sciences.
Facts about lithium
Lithium is the leading treatment for patients with bipolar disorder. There is a large variability across patient responses when taking lithium. This variability makes it difficult for clinicians to predict how patients will respond to being prescribed lithium.
For more information about Monsenso and their mHealth solution, please contact Helen Chen, Marketing, T. +45 2129 8827, email@example.com
Read more about Funding programmes for research and innovation (Horizon 2020)
Monsenso is member of Welfare Tech.